New Infusion Center to offer groundbreaking care
TULSA, OK – GRAND Mental Health (GRAND) is revolutionizing depression treatment in Oklahoma with the new GRAND Infusion Center. This concept is designed to target and eliminate major depression symptoms with the latest, FDA-approved treatment.
Of the growing number of Americans with depression, 30% are diagnosed with Treatment-Resistant Major Depressive Disorder (TRD). This persistent form of depression is known to cause suicidal thoughts or actions and is unresponsive to existing antidepressant medications that focus on serotonin and dopamine. This new center aims to eradicate TRD through the use of Spravato (Esketamine), a treatment that shifts alternative brain chemicals to ease or reduce symptoms of depression.
“Depression rates continue to rise along with the need for accessible and affordable mental health care,” stated Larry Smith, Chief Executive Officer of GRAND. “We are here to break down the barriers that keep people from the treatment they need.”
In the Infusion Center, located in the Skyline East II building in Tulsa, patients will self-administer an intra-nasal spray under the supervision of a licensed healthcare provider. Patients will remain under observation in the clinic for approximately two hours. Within these two hours, some patients often describe increased calm and less distress from their depression. For some patients, there is a significant and immediate decrease in depressive symptoms that they are unable to achieve through more traditional antidepressant medications.
“We are continuing to enhance our array of innovative treatment services both in Tulsa and across northeastern/north central Oklahoma,” shared Josh Cantwell, Chief Operating Officer of GRAND. “The Infusion Center is just one example of the state-of-the-art services we have planned for our expanding Tulsa campus.”
Psychiatrist Kahlil Michael Saliba, M.D. will lead the GRAND Infusion Center. Dr. Saliba is double board certified with the American Board of Psychiatry and Neurology for both General psychiatry and Child and Adolescent psychiatry. His extensive experience with ADHD and mood disorders such as depression and bipolar disorders, as well as his expertise in pioneering advanced treatment medications for major depressive disorders, provides GRAND an invaluable asset to patient care.
Collectively, the GRAND Infusion Center treatment team has over 25 years of experience in the medical field, with specialized experience in the area of Treatment Resistant Major Depressive Disorder, including Ketamine treatment. The team played a vital role in the state of Oklahoma’s Spravato (Esketamine) launch, after FDA approval in March 2019.
About GRAND Mental Health
GRAND Mental Health provides services for adults, children, adolescents, and families struggling with behavioral health issues, substance use issues, and integrated/medical needs in northeastern and north central Oklahoma. In business since 1979, GRAND Mental Health is a Certified Community Behavioral Health Clinic (CCBHC) providing evidence- based mental health and substance use services integrated with primary health care. Becoming a CCBHC has allowed GRAND Mental Health to hire wellness coaches, dieticians, occupational therapists, behavioral health coaches and peer recovery support specialists to provide a larger spectrum of services to clients. GRAND Mental Health operates 27 clinics and centers in 13 Oklahoma counties, employing more than 1,700 people. GRAND Mental Health strives to provide personalized care, anytime, anywhere. GRAND Mental Health works closely with and is partially funded by the Oklahoma Department of Mental Health and Substance Abuse Services.